Peregrine's Bavituximab Shows Promising Anti-Viral Activity and Signs of Prolonged Anti-Viral Effect in Single Dose Monotherapy HCV Trial

Peregrine Pharmaceuticals' Bavituximab Shows Potential Activity Against Avian Flu in Initial Testing

Peregrine Pharmaceuticals Announces New DOD Grant to Study Bavituximab (Tarvacin) in Breast Cancer

Peregrine Pharmaceuticals Transitions Tarvacin Name to Official Generic Name Bavituximab

Peregrine Pharmaceuticals Announces $4.9 Million Equity Financing

Preclinical Studies Presented at AACR Meeting Show Potential of Peregrine's Tarvacin(TM) Plus Radiation or Chemotherapy to Increase Survival in Resistant Breast Cancer and Brain Cancer

Peregrine Pharmaceuticals Files Shelf Registration Statement

Peregrine Pharmaceuticals Adopts Stockholder Rights Agreement

Peregrine Pharmaceuticals Reports Fiscal Year 2006 Third Quarter Results

Peregrine Pharmaceuticals to Announce Third Quarter FY 2006 Financial Results on March 13, 2006